- Trial Phase
- Approved
- Time to Market
- Already approved and marketed since April 2019.
- Why 4/10
- EVENITY is already approved and commercially launched with no pending regulatory decision, pivotal readout, or label-expansion catalyst identified in the next 12 months. The drug is a meaningful growth driver for Amgen but Amgen is a large, diversified biotech with many products, so Evenity alone does not drive a binary stock move. Per the rubric, an approved drug with no upcoming binary catalyst scores 3-5; 4 reflects its commercial momentum but lack of a hard dated catalyst.
EVENITY has no near-term binary catalysts. The key metric to watch is its quarterly sales trajectory, which has been accelerating (39% growth in Q3 2026). Any slowdown in that growth rate or news about cardiovascular safety litigation would be the main bearish signals, while continued market share gains or a potential FDA label expansion to include men (already approved in Europe) would be bullish. The next scheduled update will be Amgen's Q4 2026 earnings, likely in early February 2027.
Price Chart
Executive Summary
EVENITY (romosozumab) is an FDA-approved osteoporosis drug from Amgen (co-developed with UCB) that uniquely both builds bone and slows bone loss by blocking the sclerostin protein. Approved in April 2019 for postmenopausal women at high fracture risk, it carries a boxed warning for cardiovascular risks. The drug is a commercial success: Q3 2026 sales hit $751 million, up 39% year-over-year, making it one of Amgen's fastest-growing products. However, with no pending regulatory catalysts or pivotal readouts, the stock-moving potential of this single drug is limited for a company of Amgen's size and diversification.
How It Works
EVENITY is a monoclonal antibody (a lab-made protein that mimics the immune system) that blocks sclerostin, a protein that normally limits bone formation. By blocking sclerostin, EVENITY both stimulates new bone growth and slows down bone breakdown, giving it a dual effect that distinguishes it from most other osteoporosis drugs, which only slow bone loss.
Trial Status
EVENITY was FDA-approved on April 9, 2019 for the treatment of osteoporosis in postmenopausal women at high risk for fracture, based on the pivotal Phase 3 FRAME and ARCH trials. It carries a boxed warning for increased risk of myocardial infarction, stroke, and cardiovascular death, and should not be used in patients who had a heart attack or stroke within the prior year. A Phase 3 study in postmenopausal Chinese women with osteoporosis completed in 2023. The drug is also approved for osteoporosis in men in some regions (EMA label) but the FDA label is limited to postmenopausal women.
The Two-Sided Case
Upcoming Catalysts
- No specific upcoming regulatory catalysts or pivotal readouts identified for EVENITY in the next 12 months. The drug is already approved and commercialized.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Amgen PRESS-RELEASE AMGN ·Originating report